A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [(11)C]GSK2256098

BACKGROUND: GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a phase I study, the safety, tol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Brown, Nicholas F, Williams, Matthew, Arkenau, Hendrik-Tobias, Fleming, Ronald A, Tolson, Jerry, Yan, Li, Zhang, Jianping, Singh, Rajendra, Auger, Kurt R, Lenox, Laurie, Cox, David, Lewis, Yvonne, Plisson, Christophe, Searle, Graham, Saleem, Azeem, Blagden, Sarah, Mulholland, Paul
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231205/
https://ncbi.nlm.nih.gov/pubmed/29788497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy078
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars